Publications & Talks
Our Research / Publications & Talks
Design of a phase 3, randomized, placebo-controlled trial of tofersen initiated in clinically presymptomatic SOD1 mutation carriers: The ATLAS Study
Benatar M (presenter), Wuu J, Andersen PM, Andrews J, Bucelli RC, Otto M, Ferguson TA, Chen W, Fanning L, Graham D, Sun P, Liu Y, Wong J, Fradette S. Design of a phase 3, randomized, placebo-controlled trial of tofersen initiated in clinically presymptomatic SOD1 mutation carriers: The ATLAS Study. Oral presentation at the American Academy of Neurology Virtual Annual Meeting, Apr 17-22, 2021.
Frequency, hazard, and genetic risk factors of cognitive impairment in amyotrophic lateral sclerosis (ALS).
McMillan CT (presenter), Wuu J, Hennessy L, Placek K, Clinical Research in ALS (CRiALS) Study, Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium, Canadian ALS Neuroimaging Consortium (CALSNIC), Quinn C, Elman L, Grossman M, Rampersaud E, Wu G, Taylor JP, Kalra S, Benatar M. Frequency, hazard, and genetic risk factors of cognitive impairment in amyotrophic lateral sclerosis (ALS). Invited presentation at the International Neuropsychological Society Annual Meeting (virtual), Feb 2-5, 2021.
Biomarkers for ALS therapy development.
Benatar M (invited speaker). Biomarkers for ALS therapy development. Seminar at the Technical Univeristy of Munich, Germany, Feb, 2021.
Symptomatic and pre-symptomatic biomarkers for ALS therapy development.
Benatar M (invited speaker). Symptomatic and pre-symptomatic biomarkers for ALS therapy development. Johns Hopkins ALS Clinical Trials Unit, Jan, 2021.
ALS Therapy Development.
Benatar M (invited speaker). ALS Therapy Development. 44th Annual Jerome K Merlis Lectureship in Neuroscience. Department of Neurology, University of Maryland School of Medicine, Baltimore, MD, October 2020.
Conceptual framework and strategies for studying pre-symptomatic ALS.
Benatar M (presenter), Wuu J. Conceptual framework and strategies for studying pre-symptomatic ALS. 1st International Pre-Symptomatic ALS Workshop, Miami, FL, Jan 27, 2020.
Biomarkers for ALS Therapy Development.
Benatar M (invited speaker). Biomarkers for ALS Therapy Development. 5th Ottawa International Conference on Neuromuscular Disease and Biology. Ottawa, Canada, October 2019.
Biomarker Validation.
Benatar M (invited speaker). Biomarker Validation. Target ALS Annual Meeting. Boston, MA, May 2018.
ALS Therapy Development: Challenges and Opportunities.
Benatar M (invited speaker). ALS Therapy Development: Challenges and Opportunities. Platform presentation at the International Conference on Neuromuscular Disease. Toronto, Canada, July 2016.
Lessons for Charcot-Marie Tooth (CMT) Clinical Trials from ALS Experience.
Benatar M (invited speaker). Lessons for Charcot-Marie Tooth (CMT) Clinical Trials from ALS Experience. Inherited Neuropathic Consortium Annual Meeting. Miami, FL, January 2016.
Challenges and Opportunities in ALS Therapy Development.
Benatar M (invited speaker). Challenges and Opportunities in ALS Therapy Development. Ottawa International Conference on Neuromuscular Biology, Disease and Therapy. Ottawa, Canada, September 2015.
Challenges and Opportunities in ALS Therapy Development.
Flinders University Center for Neuroscience Seminar. Adelaide, Australia, September 2015.
Genetic Advances in ALS: Insights and Implications.
Benatar M (invited speaker). Genetic Advances in ALS: Insights and Implications. University of Iowa Annual Neurogenetics Meeting. Iowa City, IA, October 2015.
Challenges and Opportunities in ALS Therapy Development.
Benatar M (invited speaker). Challenges and Opportunities in ALS Therapy Development. Congress on Motor and Cognitive Degenerative Diseases. Yachay, Ecuador, January 2015.
ALS Therapy Development: Challenges and Opportunities.
Benatar M (invited speaker). ALS Therapy Development: Challenges and Opportunities. ALS Association Wisconsin Chapter. Milwaukee, WI, May 2014.